Paper published in a journal (Scientific congresses and symposiums)
Phase III study of Ribociclib (LEE011) plus Fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have received no or only one line of prior endocrine treatment : MONALEESA-3
Fasching, P.A.; JERUSALEM, Guy; Pivot, X.et al.
2016 • In Journal of Clinical Oncology, 34, p. 624
JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Service d'oncologie médicale
Pivot, X.
Martin, M.
De Laurentiis, M
Blackwell, K.L.
Esteva, F.J.
Chia, S.K.L.
Germa, C.
Tang, Z.
Dhuria, S.V.
Slamon, D.J
Language :
English
Title :
Phase III study of Ribociclib (LEE011) plus Fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have received no or only one line of prior endocrine treatment : MONALEESA-3
Publication date :
2016
Event name :
2016 ASCO Annual Meeting
Event place :
Chicago, United States
Event date :
3-7 June 2016
Audience :
International
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
